Development of a C1q-immobilized (Cim) assay to measure total antibodies to infliximab and its clinical relevance in patients with inflammatory bowel disease.
Cytokine
; 120: 54-61, 2019 08.
Article
in En
| MEDLINE
| ID: mdl-31003189
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biological Assay
/
Inflammatory Bowel Diseases
/
Complement C1q
/
Immobilized Proteins
/
Infliximab
/
Antibodies
Type of study:
Etiology_studies
Aspects:
Patient_preference
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Cytokine
Journal subject:
ALERGIA E IMUNOLOGIA
Year:
2019
Document type:
Article
Affiliation country:
Japan
Country of publication:
United kingdom